173 related articles for article (PubMed ID: 36306517)
1. National Control Laboratory Assessment of Quality of Rituximab Biosimilars in India.
Mishra NN; Sharma A; Shalini S; Sharma S; Jain P; Sharma RK; Chander H; Prasad JP; Anvikar AR; Chand S
Monoclon Antib Immunodiagn Immunother; 2022 Oct; 41(5):260-274. PubMed ID: 36306517
[TBL] [Abstract][Full Text] [Related]
2. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
Cerutti ML; Pesce A; Bès C; Seigelchifer M
BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214
[TBL] [Abstract][Full Text] [Related]
3. Comparative analytical profiling of bevacizumab biosimilars marketed in India: a national control laboratory study.
Prakash A; Mishra NN; Vaish U; Sharma S; Anand A; Mahajan RV; Prasad JP; Chand S
3 Biotech; 2020 Dec; 10(12):516. PubMed ID: 33194520
[TBL] [Abstract][Full Text] [Related]
4. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.
Nupur N; Chhabra N; Dash R; Rathore AS
MAbs; 2018 Jan; 10(1):143-158. PubMed ID: 29200314
[TBL] [Abstract][Full Text] [Related]
5. SpeB proteolysis with imaged capillary isoelectric focusing for the characterization of domain-specific charge heterogeneities of reference and biosimilar Rituximab.
Zhang Z; Perrault R; Zhao Y; Ding J
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 May; 1020():148-57. PubMed ID: 27038651
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
[TBL] [Abstract][Full Text] [Related]
7. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.
Lee KH; Lee J; Bae JS; Kim YJ; Kang HA; Kim SH; Lee SJ; Lim KJ; Lee JW; Jung SK; Chang SJ
MAbs; 2018 Apr; 10(3):380-396. PubMed ID: 29469653
[TBL] [Abstract][Full Text] [Related]
8. Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab.
Cuello HA; Segatori VI; Alberto M; Pesce A; Alonso DF; Gabri MR
BioDrugs; 2016 Jun; 30(3):225-31. PubMed ID: 27053342
[TBL] [Abstract][Full Text] [Related]
9. Assessing analytical comparability of biosimilars: GCSF as a case study.
Nupur N; Singh SK; Narula G; Rathore AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():165-171. PubMed ID: 27289250
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®.
Xu Y; Xie L; Zhang E; Gao W; Wang L; Cao Y; Xie MH; Jiang W; Liu S
MAbs; 2019 Apr; 11(3):606-620. PubMed ID: 30794092
[TBL] [Abstract][Full Text] [Related]
11. Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product.
Singh SK; Pokalwar S; Bose S; Gupta S; Almal S; Ranbhor RS
Biologics; 2018; 12():159-170. PubMed ID: 30538425
[TBL] [Abstract][Full Text] [Related]
12. Assessment of structural and functional similarity of biosimilar products: Bevacizumab as a case study.
Bhattacharya S; Rathore AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Sep; 1229():123896. PubMed ID: 37776677
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.
Joshi S; Rathore AS
BioDrugs; 2020 Apr; 34(2):209-223. PubMed ID: 31975160
[TBL] [Abstract][Full Text] [Related]
14. Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product.
Halim LA; Márquez M; Maas-Bakker RF; Castañeda-Hernández G; Jiskoot W; Schellekens H
Pharm Res; 2018 Oct; 35(11):226. PubMed ID: 30280277
[TBL] [Abstract][Full Text] [Related]
15. Cutting-edge capillary electrophoresis characterization of monoclonal antibodies and related products.
Gahoual R; Beck A; Leize-Wagner E; François YN
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():61-78. PubMed ID: 27265157
[TBL] [Abstract][Full Text] [Related]
16. Assessing the Structural and Functional Similarity of Insulin Glargine Biosimilars.
Vishwakarma G; Nupur N; Rathore AS
J Diabetes Sci Technol; 2023 Mar; 17(2):417-427. PubMed ID: 34852652
[TBL] [Abstract][Full Text] [Related]
17. Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering.
Trabik YA; Moenes EM; Al-Ghobashy MA; Nebsen M; Ayad MF
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1159():122359. PubMed ID: 32920338
[TBL] [Abstract][Full Text] [Related]
18. Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat.
Zhao YY; Wang N; Liu WH; Tao WJ; Liu LL; Shen ZD
PLoS One; 2016; 11(3):e0151874. PubMed ID: 26987122
[TBL] [Abstract][Full Text] [Related]
19. Post-translational modifications comparative identification and kinetic study of infliximab innovator and biosimilars in serum using capillary electrophoresis-tandem mass spectrometry.
Reinert T; Houzé P; Mignet N; Francois YN; Gahoual R
J Pharm Biomed Anal; 2023 Sep; 234():115541. PubMed ID: 37399702
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
